Crucell (www.crucell.com) will serve as the exclusive distributor of Talecris Biotherapeutics’ (www.talecris.com) Prolastin® (alpha-1 proteinase inhibitor) in nine Western European countries, replacing current distributor, Bayer (www.bayer.com). The product is indicated for chronic augmentation therapy of individuals having hereditary deficiency of alpha-1 proteinase inhibitor with clinically demonstrable panacinar emphysema.
